Patents by Inventor Alex Aimetti

Alex Aimetti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders
    Patent number: 12268696
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 3, 2024
    Date of Patent: April 8, 2025
    Assignee: Marinus Pharmaceuticals, Inc.
    Inventors: Joseph Hulihan, Alex Aimetti, Scott Braunstein
  • Ganaxolone for use in treatment of status epilepticus
    Patent number: 12246026
    Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: March 11, 2025
    Assignee: Marinus Pharmaceuticals, Inc.
    Inventors: David Czekai, Maciej Gasior, Lorianne Masuoka, Julia Tsai, Joseph Hulihan, Alex Aimetti
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS
    Publication number: 20250032512
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 10, 2024
    Publication date: January 30, 2025
    Inventors: Joseph HULIHAN, Alex AIMETTI, Scott BRAUNSTEIN
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS
    Publication number: 20250025476
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 3, 2024
    Publication date: January 23, 2025
    Inventors: Joseph HULIHAN, Alex Aimetti, Scott Braunstein
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS
    Publication number: 20250025477
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 3, 2024
    Publication date: January 23, 2025
    Inventors: Joseph HULIHAN, Alex AIMETTI, Scott BRAUNSTEIN
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS
    Publication number: 20250025475
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 3, 2024
    Publication date: January 23, 2025
    Inventors: Joseph HULIHAN, Alex AIMETTI, Scott BRAUNSTEIN
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX
    Publication number: 20240374614
    Abstract: The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.
    Type: Application
    Filed: February 29, 2024
    Publication date: November 14, 2024
    Inventors: Alex AIMETTI, Joseph HULIHAN, Scott BRAUNSTEIN
  • Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders
    Patent number: 12115169
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 5, 2024
    Date of Patent: October 15, 2024
    Assignee: Marinus Pharmaceuticals, Inc.
    Inventors: Joseph Hulihan, Alex Aimetti, Scott Braunstein
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS
    Publication number: 20240173336
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 5, 2024
    Publication date: May 30, 2024
    Inventors: Joseph HULIHAN, Alex AIMETTI, Scott BRAUNSTEIN
  • Ganaxolone for use in treating tuberous sclerosis complex
    Patent number: 11980625
    Abstract: The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.
    Type: Grant
    Filed: April 26, 2023
    Date of Patent: May 14, 2024
    Assignee: Marinus Pharmaceuticals, Inc.
    Inventors: Alex Aimetti, Joseph Hulihan, Scott Braunstein
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX
    Publication number: 20240100067
    Abstract: The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.
    Type: Application
    Filed: April 26, 2023
    Publication date: March 28, 2024
    Inventors: Alex AIMETTI, Joseph HULIHAN, Scott BRAUNSTEIN
  • GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
    Publication number: 20230405021
    Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.
    Type: Application
    Filed: August 28, 2023
    Publication date: December 21, 2023
    Inventors: David CZEKAI, Maciej GASIOR, Lorianne MASUOKA, Julia TSAI, Joseph HULIHAN, Alex AIMETTI
  • USE OF GANAXOLONE IN TREATING AN EPILEPSY DISORDER
    Publication number: 20230321117
    Abstract: The disclosure to methods for treating seizure or an epilepsy disorder comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 5, 2023
    Publication date: October 12, 2023
    Inventors: Alex Aimetti, Joseph HULIHAN
  • Ganaxolone for use in treating tuberous sclerosis complex
    Patent number: 11701367
    Abstract: The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: July 18, 2023
    Assignee: Marinus Pharmaceuticals, Inc.
    Inventors: Alex Aimetti, Joseph Hulihan, Scott Braunstein
  • Ganaxolone for use in treatment of status epilepticus
    Patent number: 11679117
    Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.
    Type: Grant
    Filed: April 26, 2022
    Date of Patent: June 20, 2023
    Assignee: Marinus Pharmaceuticals, Inc.
    Inventors: David Czekai, Maciej Gasior, Lorianne Masuoka, Julia Tsai, Joseph Hulihan, Alex Aimetti
  • GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
    Publication number: 20220265680
    Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.
    Type: Application
    Filed: April 26, 2022
    Publication date: August 25, 2022
    Inventors: David CZEKAI, Maciej GASIOR, Lorianne MASUOKA, Julia TSAI, Joseph HULIHAN, Alex AIMETTI
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX
    Publication number: 20220211723
    Abstract: The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.
    Type: Application
    Filed: March 1, 2022
    Publication date: July 7, 2022
    Inventors: Alex AIMETTI, Joseph HULIHAN, Scott BRAUNSTEIN
  • GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
    Publication number: 20220202831
    Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.
    Type: Application
    Filed: August 4, 2021
    Publication date: June 30, 2022
    Inventors: David CZEKAI, Maciej GASIOR, Lorianne MASUOKA, Julia TSAI, Joseph HULIHAN, Alex AIMETTI
  • Ganaxolone for use in prophylaxis and treatment of postpartum depression
    Patent number: 11266662
    Abstract: Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described. A dose of ganaxolone is administered to a female suffering from postpartum depression or at risk of developing postpartum depression in an amount and at a rate sufficient to alleviate at least one symptom of postpartum depression in the female.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: March 8, 2022
    Assignee: Marinus Pharmaceuticals, Inc.
    Inventors: Alex Aimetti, Christopher Cashman, Lorianne Masuoka, Jaakko Lappalainen
  • Ganaxolone for use in treatment of status epilepticus
    Patent number: 11110100
    Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: September 7, 2021
    Assignee: Marinus Pharmaceuticals, Inc.
    Inventors: David Czekai, Maciej Gasior, Lorianne Masuoka, Julia Tsai, Joseph Hulihan, Alex Aimetti